West Pharmaceutical Services, Inc. (WST) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging componen...
West Pharmaceutical Services, Inc.'s revenue increased 6.3% year over year, from $2.89B to $3.07B.
Net income increased 0.2% over the same period, from $492.7M to $493.7M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 104% in total.
Total debt remained relatively stable at $202.8M.
The debt-to-equity ratio stands at 0.06, indicating a conservative leverage profile.
Operating cash flow grew 15.5% to $754.8M.
West Pharmaceutical Services, Inc. maintains a healthy net profit margin of 16.1%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $2.22B+50.8% | $456.4M | $851.0M | $515.1M | $537.4M | $3.75B | $152.1M | $2.87B |
| Q1 FY2024 | $695.4M-68.6% | $115.3M | $230.2M | $122.8M | $118.2M | $3.60B | $72.8M | $2.68B |
| Q2 FY2024 | $1.40B+101.0% | $226.6M | $460.2M | $249.0M | $283.2M | $3.49B | $72.9M | $2.58B |
| Q3 FY2024 | $2.14B+53.4% | $362.6M | $724.9M | $410.3M | $463.3M | $3.68B | $202.6M | $2.75B |
| Q1 FY2025 | $698.0M-67.5% | $89.8M | $231.9M | $107.0M | $129.4M | $3.62B | $202.6M | $2.68B |
| Q2 FY2025 | $1.46B+109.8% | $221.6M | $505.8M | $260.7M | $306.5M | $3.95B | $202.6M | $2.93B |
| Q3 FY2025 | $2.27B+54.9% | $361.6M | $800.1M | $428.3M | $503.7M | $4.11B | $202.7M | $3.05B |
| Q1 FY2026 | $844.9M-62.8% | $138.8M | $296.4M | $177.1M | $89.9M | $4.11B | $202.8M | $2.99B |